MASLD and MASH

This episode delivers a comprehensive clinical review of metabolic dysfunction associated steatotic liver disease (MASLD) and its progressive stage, metabolic dysfunction associated steatohepatitis (MASH). We explore the multi organ pathogenic cascade driven by insulin resistance and lipotoxicity. Listeners will gain practical insights into non invasive risk stratification using the FIB-4 index and transient elastography, alongside evidence based management strategies spanning targeted pharmacotherapies like resmetirom, incretin mimetics, and structured lifestyle modifications.